prucalopride (Resotran, Motegrity)
Jump to navigation
Jump to search
Indications
Contraindications
- Crohn's disease
- ulcerative colitis
- toxic megacolon/megarectum
Dosage
Adverse effects
- headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, fatigue[2]
- depression, reports of suicidal ideation (monitor)
- uncharacterized (on list of drugs to avoid)[1]
Mechanism of action
- 5-HT4 receptor agonist
- stimulates colonic peristalsis
More general terms
References
- ↑ Jump up to: 1.0 1.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
- ↑ Jump up to: 2.0 2.1 Brooks M FDA OKs Prucalopride (Motegrity) for Chronic Idiopathic Constipation. Medscape - Dec 18, 2018. https://www.medscape.com/viewarticle/906732
- ↑ Jump up to: 3.0 3.1 Musa A, Geimadi A, Georgis MT et al Ogilvie Syndrome (Acute Colonic Pseudo-obstruction): Early Recognition and Treatment Are Key. Medscape. Nov 18, 2022 https://reference.medscape.com/slideshow/ogilvie-syndrome-6014904
- ↑ Lembo A, Staller K, Boules M et al Efficacy and safety of prucalopride in patients with chronic idiopathic constipation stratified by age, body mass index, and renal function: a post hoc analysis of phase III and IV, randomized, placebo-controlled clinical studies. Therap Adv Gastroenterol. 2024 Dec 10;17:17562848241299731. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39664231 PMCID: PMC11632959 Free PMC article https://journals.sagepub.com/doi/10.1177/17562848241299731
- ↑ Staller K, Hinson J, Kerstens R, Spalding W, Lembo A. Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating. Am J Gastroenterol. 2022 Jan 1;117(1):184-188. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34585675 PMCID: PMC8715996 Free PMC article. Clinical Trial.